{
  "trial_id": "NCT01787331",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Race, Ethnicity, Body Mass Index (BMI), Baseline PSA level, Prior androgen deprivation therapy (ADT) status, Serum testosterone level, PSA doubling time (PSADT), Total bilirubin level, Alanine aminotransferase (ALT) level, Aspartate aminotransferase (AST) level, Serum potassium level, Blood pressure, Eastern Cooperative Oncology Group (ECOG) performance status, Estimated life expectancy, Ability to swallow study drug, Use of birth control methods, History of hypertension, History of congestive heart failure, History of chronic active hepatitis, History of peripheral neuropathy, Use of 5-alpha reductase antagonists, Use of systemic steroids, Use of medications or herbal supplements affecting PSA, Use of other investigational agents, Prior pathology of small cell carcinoma or neuroendocrine differentiation.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Race (NIH/OMB)",
          "Race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "Ethnicity"
        ],
        [
          "PSA doubling time at the time of study entry",
          "PSA doubling time (PSADT)"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Years since diagnosis of prostate cancer",
        "Gleason Grade at Time of Diagnosis",
        "Time interval from biochemical relapse to study entry"
      ],
      "remaining_candidate_features": [
        "Body Mass Index (BMI)",
        "Baseline PSA level",
        "Prior androgen deprivation therapy (ADT) status",
        "Serum testosterone level",
        "Total bilirubin level",
        "Alanine aminotransferase (ALT) level",
        "Aspartate aminotransferase (AST) level",
        "Serum potassium level",
        "Blood pressure",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "Estimated life expectancy",
        "Ability to swallow study drug",
        "Use of birth control methods",
        "History of hypertension",
        "History of congestive heart failure",
        "History of chronic active hepatitis",
        "History of peripheral neuropathy",
        "Use of 5-alpha reductase antagonists",
        "Use of systemic steroids",
        "Use of medications or herbal supplements affecting PSA",
        "Use of other investigational agents",
        "Prior pathology of small cell carcinoma or neuroendocrine differentiation."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, PSA level, PSA doubling time, Prior androgen deprivation therapy, Serum testosterone level, ECOG performance status, Total bilirubin, ALT, AST, Serum potassium, Blood pressure, Estimated life expectancy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "PSA doubling time at the time of study entry",
          "PSA doubling time"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Ethnicity (NIH/OMB)",
        "Years since diagnosis of prostate cancer",
        "Gleason Grade at Time of Diagnosis",
        "Time interval from biochemical relapse to study entry"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "PSA level",
        "Prior androgen deprivation therapy",
        "Serum testosterone level",
        "ECOG performance status",
        "Total bilirubin",
        "ALT",
        "AST",
        "Serum potassium",
        "Blood pressure",
        "Estimated life expectancy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, PSA at Screening, PSA Doubling Time, Serum Testosterone, Prior Androgen Deprivation Therapy, Prior Local Therapy, ECOG Performance Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "PSA doubling time at the time of study entry",
          "PSA Doubling Time"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Ethnicity (NIH/OMB)",
        "Years since diagnosis of prostate cancer",
        "Gleason Grade at Time of Diagnosis",
        "Time interval from biochemical relapse to study entry"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "PSA at Screening",
        "Serum Testosterone",
        "Prior Androgen Deprivation Therapy",
        "Prior Local Therapy",
        "ECOG Performance Status"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, prostate-specific antigen (PSA) at baseline, PSA doubling time, serum testosterone level, histologic grade, Gleason score, prior local therapy, prior androgen deprivation therapy, duration of prior androgen deprivation therapy, time since prior local therapy, time since biochemical relapse.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "PSA doubling time at the time of study entry",
          "PSA doubling time"
        ],
        [
          "Gleason Grade at Time of Diagnosis",
          "Gleason score"
        ],
        [
          "Time interval from biochemical relapse to study entry",
          "time since biochemical relapse"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Years since diagnosis of prostate cancer"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "prostate-specific antigen (PSA) at baseline",
        "serum testosterone level",
        "histologic grade",
        "prior local therapy",
        "prior androgen deprivation therapy",
        "duration of prior androgen deprivation therapy",
        "time since prior local therapy"
      ]
    }
  }
}